Skip to main content
SpringerLink
Log in

NORPLANTR Contraceptive Implants

  • Chapter
Contraception

Part of the book series: Clinical Perspectives in Obstetrics and Gynecology ((CPOG))

  • 138 Accesses

Abstract

NORPLANTR contraceptive implants continuously release levonorgestrel, a synthetic progestin, at a dose sufficient to prevent pregnancy for a five-year period. By providing a steroid systemically for so long an effective period, these implants represent the first major innovation in contraceptive delivery systems in 20 years. To users, NORPLANTR implants are a highly convenient as well as an effective mode of contraception. From placement to removal five years later, a woman need take no further measures to protect herself against unwanted pregnancy. Average annual pregnancy rates in the five-year period are below one per 100 continuing users per year.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. NORPLANTR levonorgestrel implants: a summary of scientific data. New York, The Population Council, 1990; 1–30.

    Google Scholar 

  2. Diaz S, Pavez M, Herreros C, Johansson EDB, Croxatto HB. Bleeding pattern, outcome of accidental pregnancies and levonorgestrel plasma levels associated with method failure in NORPLANTR implant users. Contraception 1986; 33: 347–356.

    Article  PubMed  CAS  Google Scholar 

  3. Sivin I. International experience with NORPLANTR and NORPLANTR II contraception. Stud Fam Plan 1988; 19: 81–94.

    Article  CAS  Google Scholar 

  4. Victor A, Weiner E, Johansson EDB. Rela-tion between sex hormone binding globulin and d-norgestrel levels in plasma. Acta Endocrinol 1977; 86: 430–436.

    PubMed  CAS  Google Scholar 

  5. Affandi B, Cekan SZ, Boonkasemsanti W, Samil RS, Diczfalusy E. The interaction between sex hormone binding globulin and levonorgestrel released from NORPLANTR, an implantable contraceptive. Contraception 1987; 35: 135–145.

    Article  PubMed  CAS  Google Scholar 

  6. Olsson SE, Odlind V, Johansson EDB, Nordstrom M. Plasma levels of levonorgestrel and free levonorgestrel index in women using NORPLANTR implants of two covered rods (NORPLANTR 2). Contraception 1987; 35: 215–228.

    Article  PubMed  CAS  Google Scholar 

  7. Croxatto HB, Diaz S, Pavez M, Cardenas H, Larsson M, Johansson EDB. Clearance of levonorgestrel from the circulation following removal of NORPLANTR subdermal implants. Contraception 1988; 38: 509 - 523.

    Article  PubMed  CAS  Google Scholar 

  8. Croxatto H, Diaz S, Salvatierra AM, Morales P, Ebensperger C, Brandeis A. Treatment with NORPLANTR subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987; 39: 193–201.

    Article  Google Scholar 

  9. Brache V, Faundes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of NORPLANTR implants. Contraception 1985; 31: 261–278.

    Article  PubMed  CAS  Google Scholar 

  10. Croxatto HB, Diaz S, Pavez M, Miranda P, Brandeis A. Plasma progesterone levels during long-term treatment with levonorgestrel implants. Acta Endocrinol 1982; 101: 307–311.

    PubMed  CAS  Google Scholar 

  11. Faundes A, Brache V, Tejeda AS, Cochon MT, Alvarez-Sanchez F. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Fertil Steril 1991; 56: 27–31.

    PubMed  CAS  Google Scholar 

  12. Segal SJ, Alvarez-Sanchez F, Brache V, Faundes A, Vilja P, Tuohimaa P. NORPLANTR implants: the mechanism of contraceptive action. Fertil Steril 1991; 56: 273–277.

    PubMed  CAS  Google Scholar 

  13. Croxatto HB, Diaz S, Pavez M. Clinical chemistry in women treated with progestogen implants. Contraception 1978; 18: 441–450.

    Article  PubMed  CAS  Google Scholar 

  14. Croxatto HB, Diaz S, Robertson DN, Pavez M. Clinical chemistry in women treated with levonorgestrel implants (NORPLANTR) or a TCu 200 IUD. Contraception 1983; 27: 281–288.

    Article  PubMed  CAS  Google Scholar 

  15. Shaaban MM, Elwan SI, Abdullah SA, Darwish HA. Effect of subdermal levonorgestrel contraceptive implants, NORPLANTR, on serum lipids. Contraception 1984; 30: 413–419.

    Article  PubMed  CAS  Google Scholar 

  16. Koetsawang S, Kiriwat O, Piya-Anant M, Nukulkarn P, Panpranot C, Naewpanich P. Experience with NORPLANTR-2 in Thai women. In Ratnam SS, Teoh E-S, Lim S-M (eds): Advances in Fertility and Sterility Series, Contraception, Chapt. 20; from Proceedings of the 12 World Congress on Fertility and Sterility, Singapore, October 1986. Park Ridge, Parthenon Pub., 1987; 133–142.

    Google Scholar 

  17. Roy S, Mishell Jr, DR, Robertson DN, Krauss RM, Lacarra M, Duda MJ. Long-term reversible contraception with levonorgestrel-releasing Silastic rods. Am J Obstet Gynecol 1984; 148 (7): 1006–1013.

    PubMed  CAS  Google Scholar 

  18. Holma P, Robertson DN. Cholesterol and HDL-cholesterol values in women during use of subdermal implants releasing levonorgestrel. Contraception 1985; 32: 163–171.

    Article  PubMed  CAS  Google Scholar 

  19. Haiba N, El Sahwi MS, Toppozada M. Metabolic changes during NORPLANTR use. In Proceedings of the Symposium on Longterm Subdermal Contraceptive Implants: Egyptian and International Experience, February 23–24, 1984.

    Google Scholar 

  20. Dash DS, Das S, Nanda U, Tripathy BB, Samal KC. Serum lipid profile in women using levonorgestrel contraceptive implant, NORPLANTR. Contraception 1988; 37: 371–382.

    Article  PubMed  CAS  Google Scholar 

  21. Singh K, Viegas OAC, Ratnam SS. A three-year evaluation of metabolic changes in Singaporean NORPLANTR acceptors. Adv Contracept 1990; 6: 11–21.

    Article  PubMed  CAS  Google Scholar 

  22. Singh K, Viegas OAC, Ratnam SS. A three- year evaluation of homostatic function in Singaporean NORPLANTR acceptors. Adv Contracept 1990; 6: 23–32.

    Article  PubMed  CAS  Google Scholar 

  23. Shaaban MM, Elwan SI, El-Karasa MY, Farghaly SA, Thabet N. Effect of levonorgestrel contraceptive implants, NORPLANTR, on blood coagulation. Contraception 1984; 30: 421–430.

    Article  PubMed  CAS  Google Scholar 

  24. Gu S, Du M, Yuan DY, Zhang LD, Xu MF, Liu Y-L, Wang SH, Wu SL, Wang P-Z, Gao Y-L, He X, Zi L-F, Chen C-R, Liu YP, Mo P, Sivin I. A two-year study of acceptability, side effects, and effectiveness of NORPLANTR and NORPLANTR-2 implants in the People’s Republic of China. Contraception 1988; 38: 641–657.

    Article  PubMed  CAS  Google Scholar 

  25. Nilsson CG, Holma P. Menstrual blood loss with contraceptive subdermal levonorgestrel implants. Fertil Steril 1981; 35: 304–306.

    PubMed  CAS  Google Scholar 

  26. Fakeye O, Balogh S. Effect of NORPLANTR contraceptive use on hemoglobin, packed cell volume, and menstrual bleeding patterns. 33. Contraception 1989; 39: 265–274.

    Article  PubMed  CAS  Google Scholar 

  27. Faundes A, Sivin I, Stern J. Long-acting contraceptive implants. An analysis of menstrual bleeding patterns. Contraception 1978; 18: 34. 355–365.

    Article  PubMed  CAS  Google Scholar 

  28. Shaaban MM, Salah M, Zarzour A, Abdullah 35. SA. A prospective study of NORPLANTR implants and the TCu 380Ag IUD in Assiut, Egypt. Stud Fam Plan 1983; 14: 163–169.

    Article  CAS  Google Scholar 

  29. Brache V, Alvarez-Sanchez F, Faundes A, Tejeda A, Cochon L. Ovarian endocrine function through five years of continuous treatment with NORPLANTR subdermal contraceptive implants. Contraception 1990; 41: 169–177.

    Article  PubMed  CAS  Google Scholar 

  30. Alvarez F, Brache V, Tejeda AS, Faundes A. Abnormal endocrine profile among women 38. with confirmed or presumed ovulation during long-term NORPLANTR use. Contraception 1986; 33: 111–119.

    Article  PubMed  CAS  Google Scholar 

  31. Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the 39. literature. Stud Fam Plan 1987; 18: 237–283.

    Article  CAS  Google Scholar 

  32. Moreno L, Goldman N. Contraceptive failure rates in developing countries: evidence from demographic and health surveys. Intl Fam Plan Pers 1991; 17: 44–49.

    Article  Google Scholar 

  33. Croxatto H, Diaz S, Sivin I. Contraceptive implants In Seppala M, Bamberger L. Frontiers in human reproduction. In (eds): Ann NY Acad Sci. 1991; 22–29.

    Google Scholar 

  34. Sivin I, Schmidt F. Effectiveness of IUDs: a review. Contraception 1987; 36: 55–84.

    Article  PubMed  CAS  Google Scholar 

  35. Sivin I. Dose-and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78: 291–298.

    PubMed  CAS  Google Scholar 

  36. Haukkama M. Contraception by NORPLANTR subdermal capsules is not reliable in epileptic patients on anticonvulsant treatment. Contraception 1986; 33: 559–565.

    Article  Google Scholar 

  37. Odlind V, Olsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with NORPLANTR implants. Contraception 1986; 33: 257–261.

    Article  PubMed  CAS  Google Scholar 

  38. Diaz S, Croxatto HB, Pavez M, Belhadj K, Stern J, Sivin I. Clinical assessment of treatments for prolonged bleeding in users of NORPLANT11 implants. Contraception 1990; 42: 97–110.

    Article  PubMed  CAS  Google Scholar 

  39. Shoupe D, Mishell Jr DR, Bopp BL, Fielding M. The significance of bleeding patterns in NORPLANTR implant users. Obstet Gynecol 1991; 77: 256–260.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Irving Sivin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Reproductive Endocrinology and Infertility, University of Southern California School of Medicine, Women’s Hospital Room L946, 1240 North Mission Road, 90033, Los Angeles, CA, USA

    Donna Shoupe M.D. (Associate Professor) (Associate Professor)

  2. Department of Obstetrics and Gynecology, LAC-USC Medical Center, Women’s Hospital Room L946, 1240 North Mission Road, 90033, Los Angeles, CA, USA

    Donna Shoupe M.D. (Associate Professor) (Associate Professor)

  3. Center for Population Research, National Institute of Child Health and Human Development, National Institutes of Health, 20892, Bethesda, MD, USA

    Florence P. Haseltine MD, Ph.D. (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Sivin, I. (1993). NORPLANTR Contraceptive Implants. In: Shoupe, D., Haseltine, F.P. (eds) Contraception. Clinical Perspectives in Obstetrics and Gynecology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2730-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-2730-4_12

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7645-6

  • Online ISBN: 978-1-4612-2730-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation